ASRT has been the topic of several other reports. Roth Capital reaffirmed a “buy” rating on shares of Assertio in a report on Wednesday, August 24th. TheStreet raised shares of Assertio from a “d” rating to a “c-” rating in a research note on Wednesday, August 3rd.
Assertio Stock Up 2.7 %
Shares of ASRT opened at $2.25 on Friday. Assertio has a 12 month low of $0.85 and a 12 month high of $4.44. The firm’s 50 day moving average is $3.08 and its 200-day moving average is $2.89. The stock has a market capitalization of $108.40 million, a PE ratio of 4.17, a P/E/G ratio of 0.44 and a beta of 1.67. The company has a current ratio of 1.00, a quick ratio of 0.90 and a debt-to-equity ratio of 0.39.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its position in Assertio by 4.5% in the second quarter. Northern Trust Corp now owns 78,745 shares of the company’s stock valued at $232,000 after buying an additional 3,399 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in Assertio by 3.9% in the second quarter. Thompson Siegel & Walmsley LLC now owns 169,473 shares of the company’s stock valued at $500,000 after buying an additional 6,329 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Assertio in the second quarter valued at approximately $28,000. Cubist Systematic Strategies LLC boosted its position in Assertio by 14.4% in the second quarter. Cubist Systematic Strategies LLC now owns 77,424 shares of the company’s stock valued at $228,000 after buying an additional 9,755 shares in the last quarter. Finally, Sigma Planning Corp acquired a new stake in Assertio in the second quarter valued at approximately $32,000. 27.93% of the stock is owned by institutional investors.
Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
- Get a free copy of the StockNews.com research report on Assertio (ASRT)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.